The FY22 Defense Appropriations Act is anticipated to provide funding for the KCRP to support research of exceptional scientific merit in the area of kidney cancer.  The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).

The FY22 KCRP funding opportunity announcements for the following award mechanisms are posted on the Grants.gov website. 

Applications submitted to the FY22 KCRP must address one or more of the following Focus Areas:

• Conduct basic biology research to better understand etiology and cancer progression, metastatic disease, refractory disease and therapeutic resistance, genetic and environmental risk factors and the prevention of kidney cancer.
• Define the biology of rare kidney cancers and develop treatments to improve outcomes and reduce death.
• Identify and develop new strategies for screening, early-stage detection, accurate diagnosis and prognosis prediction of kidney cancers, with examples including biomarkers and imaging.
• Develop novel therapeutic strategies for the treatment of kidney cancer, such as novel drug targets, therapeutic modalities and agents, treatment combinations, and drug delivery systems.
• Identify and implement strategies to improve the quality of life and survivorship for patients.
• Identify and implement strategies to mitigate health disparities, such as access to healthcare, social and cultural factors, environmental factors, and biological contributors.
• Support preparation and development of the next generation of kidney cancer researchers, or cultivate collaborations in kidney cancer research or patient care in alignment with the KCRP Overarching Strategic Goals.

Funding Opportunities - FY22 Kidney Cancer Research Program, Congressionally Directed Medical Research Programs (CDMRP) (army.mil)

Academy of Kidney Cancer Scholars – Early-Career Investigator Award – Letter of Intent September 29, 2022

Must be within 4 years of last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.), or equivalent, as of full application submission deadline.

Letter attesting to eligibility required.

• ·        Supports the addition of new Early-Career Scholars to the unique, interactive virtual academy providing intensive mentoring, national networking, and a peer group for junior faculty.
• ·        Early-Career Scholars whose ability to commit to conducting kidney cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.
• ·        A Designated Mentor who is an experienced kidney cancer researcher with a record of kidney cancer funding is required.
• ·        The Designated Mentor not required to be at the same institution as the Early-Career Scholar.
• ·        Preliminary data required.
• ·        Clinical trials are not allowed.
• ·        Maximum funding of $725,000 for direct costs (plus indirect costs).
• ·        Maximum period of performance 4 years.
• ·        Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

Nurse-Initiated Research Award – Letter of Intent due September 29, 2022

Must have a Registered Nurse license and/or a Master’s or Doctoral degree in nursing.

• ·        Supports nursing research pertaining to kidney cancer patient care.
• ·        Clinical trials are not allowed; correlative studies to clinical trials are allowed. Qualified Collaboration Option: Leveraging of existing infrastructure of a federally funded partnership/consortium is encouraged.
• ·        •Maximum funding of $300,000 for direct costs (plus indirect costs).
• ·        •Maximum period of performance is 2 years.
• ·        •Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

Clinical Trial Award Modified for FY22 – Letter of Intent due September 29, 2022

Independent investigators at all levels.

•                  Supports projects ranging from small proof-of-concept trials (e.g., pilot, first in human, phase 0) to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations.

•                  Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies.

•                  Investigational New Drug (IND) or Investigational Device Exemption (IDE) application, if applicable, must be submitted to the U.S. Department of Food and Drug Administration (FDA) by the time of application submission.

•                  Documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate, for the proposed duration of the study must be provided.

•                  Clinical trials are expected to begin no later than 12 months after the award date, or 18 months after the award date for FDA-regulated studies.

•                  Qualified Collaboration Option: Leveraging of existing infrastructure of a federally funded partnership/consortium is encouraged.

•                  Maximum funding of

• ·        $1,500,000 for direct costs (plus indirect costs).

•                  Maximum period of performance is 4 years.

•                  Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

• ·        Cell Therapy Focus Option:

•                  Maximum funding of

• ·        $2,000,000 for direct costs (plus indirect costs).

•                  Maximum period of performance is 4 years.

•                  Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final funding opportunity announcements that will be available for downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the KCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507
help@eBrap.org

For more information, please contact Jill Sherman, International Research Facilitator, at intl.research@lakeheadu.ca.

The Genomic Applications Partnership Program (GAPP) funds downstream research and development (R&D) projects that address real-world opportunities and challenges defined by “Receptor” organizations such as industry, government, or not-for-profit entities. These organizations should have the expertise, resources and commitment to commercialize or implement the project’s outcomes. Projects must be active collaborations between the Receptor organization (Canadian or international) and a Canadian academic researcher. Both must play an integral role in the project. These projects are co-funded by Receptors and other stakeholders and must have the potential to generate significant social and/or economic benefits for Canada.

The Forest Sector Investment and Innovation Program provides funding for strategic investments in the forest sector that:

• enhance competitiveness
• support new market access
• provide benefits to Ontario’s broader forest sector
• strengthen regional economies

Support is available under two project categories:

• business projects
• collaboration projects

The Cancer Therapeutics Innovation Pipeline (CTIP) Program was established to capitalize on Ontario’s expertise in cancer biology and drug discovery. Its aim is to create a pipeline of validated cancer targets and first-in-class or best-in-class, novel, selective lead molecules (small molecules or biologics) that will attract partnerships and/or investment for further preclinical and clinical development. To generate a sustainable pipeline, CTIP will support projects that aim to provide increasing evidence of target validation and disease association using data from knowledge bases, functional assays, and drug screening in relevant in vitro and in vivo models of the cancer type of interest.

The R&D Partnership Fund - Electric Vehicle (EV) – Stream 2 Program supports projects related to the development and demonstration of technologies in electric vehicles (EV) and battery manufacturing technologies in the following priority areas:

• Mass light vehicles, such as cars, trucks and vans
• Heavy duty vehicles, including commercial vehicles, trucks, buses, recreational vehicles (RVs), and others used for goods movement
• Charging infrastructure
• Intelligent Transportation Systems (ITS)
• Transit-supportive systems and vehicles

The Climate Action and Awareness Fund (CAAF) has opened the Support to Canadian Think Tanks and Academic Institutions Call for Proposals (CFP).

The objective of this call for proposals is to support research and analysis projects that will identify, accelerate, and evaluate climate mitigation solutions and strategies that will contribute to achieving net-zero greenhouse gas emissions in Canada.

Projects must align with one or more of the following research themes:

1.        Defining the future systems required for net-zero;
2.        Obstacles on the pathways to net-zero;
3.        Distributional impacts of the pathways to net-zero on workers and their communities;
4.        Motivating net-zero action

To be eligible for funding under this CFP, Lead Applicants must be one of the following:

• ·       not-for-profit non-governmental organization
• ·       university or academic institution
• ·       Indigenous organization

The deadline for submitting a proposal is 3:00 pm Eastern Standard Time (EST) on July 18, 2022.

Webinar sessions for prospective applicants about the process of submitting a proposal will be offered in English and French on June 21 and 23, 2022, respectively.

Please visit the online application platform Grants & Contributions Enterprise Management System (GCEMS) for detailed information on eligibility, to access the Applicant Guide, and to apply for funding.  For instructions on how to create an account in order to apply for funding, please click here.

For all inquiries related to the Climate Action and Awareness Fund and this funding opportunity, please email: fasc-caaf@ec.gc.ca

Amazon Research Awards (ARA) is announcing the spring 2022 call for proposals (CFP). The spring 2022 CFP, which is open for submissions, covers four research areas and reflects Amazon's ongoing efforts to collaborate with researchers in a variety of research fields.

The full list of proposal areas, including links with details on how to apply, is below. The deadline for submissions is July 8, 2022.

• AI for Information Security
• Alexa – Fairness in AI
• Amazon Advertising
• Amazon Science Community and Machine Learning University

Proposals will be reviewed for the quality of their scientific content, creativity, and potential for impact at scale. Proposals related to theory, practice, and novel techniques are all welcome.

ARA provides grant recipients unrestricted funds and AWS promotional credits. Funded projects are assigned an Amazon research contact, and recipients also receive training resources, including AWS tutorials and hands-on sessions with Amazon scientists and engineers.

The Proof of Concept Grant provides $100,000 over up to 3 years to support investigators with innovative, high-risk, high-yield hypotheses about dementia.

The Alzheimer Society Research Program will pre-screen applications for the Proof of Concept Grant through a Letter of Intent (LOI) process. Successful LOI applicants will then be asked to submit a full application for peer review later in the summer.

Researchers with big, bold, challenging new ideas relevant to Alzheimer’s disease and other dementias are encouraged to apply.

The LOI form is available now with submissions due by July 11, 2022.

Accessibility Standards Canada is inviting interested organizations to submit an expression of interest for research funding. This is the first step in applying.

Your project must align with the goals and desired outcomes of Accessibility Standards Canada’s grants and contributions program. 

If your expression of interest is selected, you will be invited to submit a detailed application. These applications will then be assessed to determine which projects will be selected for funding. You may submit more than 1 expression of interest.

To apply, you must meet all of the following program requirements.